NIH Research Grant Awarded to Foster the Development of Oral IL-23 Receptor Antagonists for IBD

NIH Research Grant Awarded to Foster the Development of Oral IL-23 Receptor Antagonists for IBD
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an institute that is part of the National Institute of Health (NIH), recently granted a Phase 1 Small Business Innovation Research Grant to Protagonist Therapeutics. The grant will foster the development of a new drug for the treatment of Inflammatory Bowel Disease (IBD). The drug

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *